J A Arnaiz

Summary

Country: Spain

Publications

  1. ncbi request reprint The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals
    J A Arnaiz
    Clinical Pharmacology, UASP, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Eur J Clin Pharmacol 57:89-91. 2001
  2. ncbi request reprint A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients
    J Mallolas
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Rev Clin Esp 207:427-32. 2007
  3. ncbi request reprint Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
    E Martinez
    Unit of Infectious Diseases, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic Universitari, Barcelona, Spain
    AIDS 15:1261-8. 2001
  4. doi request reprint Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts
    E De Lazzari
    Biostatistic Unit, Hospital Clinic, University of Barcelona, Spain
    HIV Med 9:221-6. 2008
  5. doi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
  6. doi request reprint Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
  7. ncbi request reprint Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
    W M El-Sadr
    Ann Intern Med 149:289-99. 2008

Detail Information

Publications7

  1. ncbi request reprint The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals
    J A Arnaiz
    Clinical Pharmacology, UASP, Hospital Clinic, Villarroel 170, 08036 Barcelona, Spain
    Eur J Clin Pharmacol 57:89-91. 2001
    ..Withdrawal of a drug from the market for safety reasons is a serious and sometimes complex decision. The scientific evidence supporting drug withdrawals in the past years is critically appraised...
  2. ncbi request reprint A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients
    J Mallolas
    Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
    Rev Clin Esp 207:427-32. 2007
    ....
  3. ncbi request reprint Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
    E Martinez
    Unit of Infectious Diseases, Institut d Investigacions Biomediques August Pi i Sunyer, Hospital Clinic Universitari, Barcelona, Spain
    AIDS 15:1261-8. 2001
    ..To assess the incidence and risk factors for hepatotoxicity associated with nevirapine...
  4. doi request reprint Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts
    E De Lazzari
    Biostatistic Unit, Hospital Clinic, University of Barcelona, Spain
    HIV Med 9:221-6. 2008
    ..It is unclear whether this higher risk also applies to stable virologically suppressed patients starting NcART...
  5. doi request reprint Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  6. doi request reprint Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  7. ncbi request reprint Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
    W M El-Sadr
    Ann Intern Med 149:289-99. 2008
    ..Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy...